ANTHONY M. MANNING, PH.D. - Corporate Board Profile

PALATIN TECHNOLOGIES INC

Filing Date	Source Excerpt
2018-05-17	ANTHONY M. MANNING, Ph.D., has been a director of Palatin since September 2017... No committees mentioned... No compensation mentioned.
2019-05-10	Anthony M. Manning, Ph.D., has been a director of Palatin since September 2017. Since 2013, Dr. Manning has been senior vice president of research, and since 2018 chief scientific officer, at Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing innovative therapeutics for rare immune-related diseases. From 2011 to 2013, he was senior vice president of research and development at Aileron Therapeutics, Inc., a publicly traded biopharmaceutical company developing stapled peptide therapeutics for cancers and other diseases. From 2007 to 2011, he was vice president and head of inflammation and autoimmune diseases research at Biogen, Inc., a publicly traded biopharmaceutical company developing medicines for neurological and neurodegenerative conditions. From 2002 to 2007, he was vice president and global therapy area head for Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals, the pharmaceutical division of Roche Holding AG, and from 2000 to 2002 he was vice president of Pharmacia, a global pharmaceutical company acquired by Pfizer in 2002. Dr. Manning received his Ph.D., M.Sc. and B.Sc. from the University of Otago, Dunedin, New Zealand. Dr. Manning serves on the Nominating and Corporate Governance Committee. For fiscal 2018, Dr. Manning received total compensation of $142,678.
2020-05-11	Anthony M. Manning, Ph.D., has been a director of Palatin since September 2017. He is a member of the nominating and corporate governance committee. For fiscal 2019, he received total compensation of $130,800.
2021-04-26	Anthony M. Manning, Ph.D., has been a director of Palatin since September 2017... He is a member of the nominating and corporate governance committee. Director compensation table shows total compensation of $133,450.
2022-05-24	Anthony M. Manning, Ph.D., has been a director of Palatin since September 2017. (1) Member of the audit committee. (3) Member of the nominating and corporate governance committee. The following table sets forth the compensation we paid to all directors during fiscal 2021, except for Dr. Spana, whose compensation is set forth below in the Fiscal 2021 Summary Compensation Table and related disclosure. Anthony Manning, Ph.D. 47,500 fees earned or paid in cash, 42,500 stock awards, 42,500 option awards, total 132,500.
2023-05-19	Anthony M. Manning, Ph.D., has been a director of Palatin since September 2017. Since March 2021, Dr. Manning has been providing scientific and strategic advice to biotechnology companies as the principal of Manning Bio Worldwide LLC. From 2013 until March 2021, Dr. Manning was senior vice president of research, and since 2018 was chief scientific officer, at Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing innovative therapeutics for rare immune-related diseases which was acquired by Johnson & Johnson in October 2020. From 2011 to 2013, he was senior vice president of research and development at Aileron Therapeutics, Inc., a publicly traded biopharmaceutical company developing stapled peptide therapeutics for cancers and other diseases. From 2007 to 2011, he was vice president and head of inflammation and autoimmune diseases research at Biogen, Inc., a publicly traded biopharmaceutical company developing medicines for neurological and neurodegenerative conditions. From 2002 to 2007, he was vice president and global therapy area head for Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals, the pharmaceutical division of Roche Holding AG, and from 2000 to 2002 he was vice president of Pharmacia, a global pharmaceutical company acquired by Pfizer in 2002. Dr. Manning received his Ph.D., M.Sc. and B.Sc. from the University of Otago, Dunedin, New Zealand. Dr. Manning has extensive experience in translational research and development of new pharmaceutical products, and in pharmaceutical and biotechnology research, development, and business strategy.
2024-05-28	Anthony M. Manning, Ph.D. has been a director of Palatin since September 2017. He is a member of the audit committee and nominating and corporate governance committee. Compensation table shows total compensation of $97,466.